← All trials
NCT05389319
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 24, 2022
- Primary completion
- Feb 28, 2023
- Completion date
- Feb 28, 2023
- First posted
- May 25, 2022
- Last posted
- Jul 14, 2022
- Enrollment
- 60
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of TuebingenLead sponsor
- FGK Clinical Research GmbHCollaborator
- Staburo GmbHCollaborator
- VisMederi srlCollaborator
- University of TuebingenOfficial
- Viedoc Technologies ABCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.